<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394755</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1</org_study_id>
    <nct_id>NCT03394755</nct_id>
  </id_info>
  <brief_title>Thrombosomes® in Bleeding Thrombocytopenic Patients</brief_title>
  <official_title>A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellphire, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellphire, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates in a dose-escalation manner, the safety, and preliminary impact on
      bleeding, and the preliminary effect on coagulation measures of increasing doses of
      allogeneic Thrombosomes in thrombocytopenic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this trial, conducted in thrombocytopenic patients with modified World
      Health Organization (WHO) Grade 1* or 2 bleeding, assessing the safety of infusing increasing
      doses of allogeneic Thrombosomes in WHO bleeding and measures of coagulation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">October 18, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in WHO Bleeding Grade</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Coagulation Measures</measure>
    <time_frame>2 days</time_frame>
    <description>Measures of PT/INR, aPTT, d-dimer, fibrinogen, TAT, PF1+2, TEG, TGA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Thrombocytopenia</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Bone Marrow Aplasia</condition>
  <arm_group>
    <arm_group_label>Thrombosomes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thrombosomes</intervention_name>
    <description>Freeze-dried platelets</description>
    <arm_group_label>Thrombosomes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults up to 74 y/o with any of following: acute leukemia (ALL or AML),
             myelodysplasia, aplasia, and/or therapy (chemotherapy or radiation) induced bone
             marrow aplasia or hypoplasia with thrombocytopenia (platelet count ≥ 5,000 and ≤
             70,000/μL) for a minimum of 2 days. May include bone marrow transplant or peripheral
             or cord blood stem cell recipients, but not subjects with Graft-vs-Host disease.

          -  Hospitalized patients (or willing to be hospitalized for 24 hours after Rx) with
             Modified WHO Grade 1 (subset) or Grade 2 Bleeding Score or at risk for same within 4
             weeks of screening. The Grade 1 subset includes patients who have either epistaxis,
             hematuria, oral petechiae, or bleeding at invasive or other wound sites.

          -  No platelet inhibitor drugs within 5 days prior to infusion and during the immediate
             study 6 Day follow-up period.

        Exclusion Criteria:

          -  Hx or condition related to thrombosis, embolism or vascular occlusion/ischemia,
             including but not limited to: TIA, stroke, MI, stent placement, valve replacement
             and/or repair

          -  Currently with an active acute infection, or suspected infection, a single oral
             temperature of ≥ 101° F or a temperature of ≥ 100.4°F sustained over a 1 h period in
             past 24 h. Subjects on prophylactic antibiotics are not excluded from study

          -  Coagulopathy or receiving anticoagulants that result in PT or aPTT values greater than
             1.3 X upper limit of normal or elevated D-dimer of decreased fibrinogen

          -  History of any inherited coagulation or platelet function, disorder or ITP, TTP, or
             HUS

          -  Receipt of tranexamic acid or other antifibrinolytics within 48 hrs prior to infusion

          -  Rx with an investigational drug w/in 1 month of infusion, other than for treatment of
             their underlying disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Fitzpatrick</last_name>
    <role>Study Director</role>
    <affiliation>Cellphire, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoxworth Blood Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thrombocytopenia</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

